Skip to main content
Erschienen in: Digestive Diseases and Sciences 2/2013

01.02.2013 | Review

Fecal Calprotectin in Pediatric Inflammatory Bowel Disease: A Systematic Review

verfasst von: Ioannis D. Kostakis, Kyriaki G. Cholidou, Aristeidis G. Vaiopoulos, Ioannis S. Vlachos, Despina Perrea, George Vaos

Erschienen in: Digestive Diseases and Sciences | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Inflammatory bowel disease frequently begins during childhood or adolescence. Current tests and procedures for diagnosing and monitoring inflammatory bowel disease are invasive, uncomfortable and costly. Fecal calprotectin is an inflammatory marker tested in several studies including pediatric patients with inflammatory bowel disease.

Methods

A search for articles published up to October 2011 was conducted using MEDLINE and EMBASE databases. We included original English-written articles referred to pediatric patients with inflammatory bowel disease and measured fecal calprotectin levels. We extracted data concerning fecal calprotectin levels in patients with inflammatory bowel disease and in the controls groups, sensitivity, specificity, positive and negative likelihood ratio.

Results

Thirty-four studies were included. Fecal calprotectin levels of patients with inflammatory bowel disease are much higher than those of healthy controls or patients with functional disorders or other gastrointestinal diseases. The results vary greatly when taking all studies into consideration. Nevertheless, in cases of newly diagnosed and/or active inflammatory bowel disease, the results are more homogeneous, with high sensitivity and positive likelihood ratio, low negative likelihood ratio, but moderate specificity. Moreover, 50 μg/g seems to be the most proper cut-off point for the fecal calprotectin test.

Conclusions

The fecal calprotectin test could be used for supporting diagnosis or confirming relapse of inflammatory bowel disease in pediatric patients. A positive result could confirm the suspicion of either inflammatory bowel disease diagnosis or inflammatory bowel disease relapse, due to the high sensitivity of the test, but a negative result should not exclude these conditions, due to its moderate specificity.
Literatur
1.
Zurück zum Zitat Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 2011;17:423–439.PubMedCrossRef Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 2011;17:423–439.PubMedCrossRef
2.
Zurück zum Zitat Dubinsky M. Special issues in pediatric inflammatory bowel disease. World J Gastroenterol. 2008;14:413–420.PubMedCrossRef Dubinsky M. Special issues in pediatric inflammatory bowel disease. World J Gastroenterol. 2008;14:413–420.PubMedCrossRef
3.
Zurück zum Zitat Carvalho R, Hyams JS. Diagnosis and management of inflammatory bowel disease in children. Semin Pediatr Surg. 2007;16:164–171.PubMedCrossRef Carvalho R, Hyams JS. Diagnosis and management of inflammatory bowel disease in children. Semin Pediatr Surg. 2007;16:164–171.PubMedCrossRef
4.
Zurück zum Zitat Rufo PA, Bousvaros A. Challenges and progress in pediatric inflammatory bowel disease. Curr Opin Gastroenterol. 2007;23:406–412.PubMedCrossRef Rufo PA, Bousvaros A. Challenges and progress in pediatric inflammatory bowel disease. Curr Opin Gastroenterol. 2007;23:406–412.PubMedCrossRef
5.
Zurück zum Zitat Kim SC, Ferry GD. Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations. Gastroenterology. 2004;126:1550–1560.PubMedCrossRef Kim SC, Ferry GD. Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations. Gastroenterology. 2004;126:1550–1560.PubMedCrossRef
6.
Zurück zum Zitat Kim S, Ferry G. Inflammatory bowel diseases in children. Curr Probl Pediatr Adolesc Health Care. 2002;32:108–132.PubMedCrossRef Kim S, Ferry G. Inflammatory bowel diseases in children. Curr Probl Pediatr Adolesc Health Care. 2002;32:108–132.PubMedCrossRef
7.
Zurück zum Zitat Shikhare G, Kugathasan S. Inflammatory bowel disease in children: current trends. J Gastroenterol. 2010;45:673–682.PubMedCrossRef Shikhare G, Kugathasan S. Inflammatory bowel disease in children: current trends. J Gastroenterol. 2010;45:673–682.PubMedCrossRef
8.
Zurück zum Zitat Baumgart DC. The diagnosis and treatment of Crohn’s disease and ulcerative colitis. Dtsch Arztebl Int. 2009;106:123–133.PubMed Baumgart DC. The diagnosis and treatment of Crohn’s disease and ulcerative colitis. Dtsch Arztebl Int. 2009;106:123–133.PubMed
9.
Zurück zum Zitat Romano C, Famiani A, Gallizzi R, Comito D, Ferrau’ V, Rossi P. Indeterminate colitis: a distinctive clinical pattern of inflammatory bowel disease in children. Pediatrics. 2008;122:e1278–e1281.PubMedCrossRef Romano C, Famiani A, Gallizzi R, Comito D, Ferrau’ V, Rossi P. Indeterminate colitis: a distinctive clinical pattern of inflammatory bowel disease in children. Pediatrics. 2008;122:e1278–e1281.PubMedCrossRef
10.
Zurück zum Zitat Hugot JP, Bellaiche M. Inflammatory bowel diseases: the paediatric gastroenterologist’s perspective. Pediatr Radiol. 2007;37:1065–1070.PubMedCrossRef Hugot JP, Bellaiche M. Inflammatory bowel diseases: the paediatric gastroenterologist’s perspective. Pediatr Radiol. 2007;37:1065–1070.PubMedCrossRef
11.
Zurück zum Zitat Merchant A. Inflammatory bowel disease in children: an overview for pediatric healthcare providers. Gastroenterol Nurs. 2007;30:278–282.PubMedCrossRef Merchant A. Inflammatory bowel disease in children: an overview for pediatric healthcare providers. Gastroenterol Nurs. 2007;30:278–282.PubMedCrossRef
12.
Zurück zum Zitat Bousvaros A, Antonioli DA, Colletti RB, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn’s and Colitis Foundation of America. J Pediatr Gastroenterol Nutr. 2007;44:653–674.PubMedCrossRef Bousvaros A, Antonioli DA, Colletti RB, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn’s and Colitis Foundation of America. J Pediatr Gastroenterol Nutr. 2007;44:653–674.PubMedCrossRef
13.
Zurück zum Zitat Leighton JA, Legnani P, Seidman EG. Role of capsule endoscopy in inflammatory bowel disease: where we are and where we are going. Inflamm Bowel Dis. 2007;13:331–337.PubMedCrossRef Leighton JA, Legnani P, Seidman EG. Role of capsule endoscopy in inflammatory bowel disease: where we are and where we are going. Inflamm Bowel Dis. 2007;13:331–337.PubMedCrossRef
14.
Zurück zum Zitat Diefenbach KA, Breuer CK. Pediatric inflammatory bowel disease. World J Gastroenterol. 2006;12:3204–3212.PubMed Diefenbach KA, Breuer CK. Pediatric inflammatory bowel disease. World J Gastroenterol. 2006;12:3204–3212.PubMed
15.
Zurück zum Zitat Odze R. Diagnostic problems and advances in inflammatory bowel disease. Mod Pathol. 2003;16:347–358.PubMedCrossRef Odze R. Diagnostic problems and advances in inflammatory bowel disease. Mod Pathol. 2003;16:347–358.PubMedCrossRef
17.
Zurück zum Zitat Wong A, Bass D. Laboratory evaluation of inflammatory bowel disease. Curr Opin Pediatr. 2008;20:566–570.PubMedCrossRef Wong A, Bass D. Laboratory evaluation of inflammatory bowel disease. Curr Opin Pediatr. 2008;20:566–570.PubMedCrossRef
18.
Zurück zum Zitat Fagerberg UL, Lööf L, Myrdal U, Hansson LO, Finkel Y. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr. 2005;40:450–455.PubMedCrossRef Fagerberg UL, Lööf L, Myrdal U, Hansson LO, Finkel Y. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr. 2005;40:450–455.PubMedCrossRef
19.
Zurück zum Zitat Bonnín Tomàs A, Vila Vidal M, Rosell Camps A. Fecal calprotectin as a biomarker to distinguish between organic and functional gastrointestinal disease. Rev Esp Enferm Dig. 2007;99:689–693.PubMedCrossRef Bonnín Tomàs A, Vila Vidal M, Rosell Camps A. Fecal calprotectin as a biomarker to distinguish between organic and functional gastrointestinal disease. Rev Esp Enferm Dig. 2007;99:689–693.PubMedCrossRef
20.
Zurück zum Zitat Sidler MA, Leach ST, Day AS. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis. 2008;14:359–366.PubMedCrossRef Sidler MA, Leach ST, Day AS. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis. 2008;14:359–366.PubMedCrossRef
21.
Zurück zum Zitat Quail MA, Russell RK, Van Limbergen JE, et al. Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:756–759.PubMedCrossRef Quail MA, Russell RK, Van Limbergen JE, et al. Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:756–759.PubMedCrossRef
22.
Zurück zum Zitat Perminow G, Beisner J, Koslowski M, et al. Defective paneth cell-mediated host defense in pediatric ileal Crohn’s disease. Am J Gastroenterol. 2010;105:452–459.PubMedCrossRef Perminow G, Beisner J, Koslowski M, et al. Defective paneth cell-mediated host defense in pediatric ileal Crohn’s disease. Am J Gastroenterol. 2010;105:452–459.PubMedCrossRef
23.
Zurück zum Zitat Canani RB, de Horatio LT, Terrin G, et al. Combined use of noninvasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2006;42:9–15.PubMedCrossRef Canani RB, de Horatio LT, Terrin G, et al. Combined use of noninvasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2006;42:9–15.PubMedCrossRef
24.
Zurück zum Zitat Bruzzese E, Raia V, Gaudiello G, et al. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Aliment Pharmacol Ther. 2004;20:813–819.PubMedCrossRef Bruzzese E, Raia V, Gaudiello G, et al. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Aliment Pharmacol Ther. 2004;20:813–819.PubMedCrossRef
25.
Zurück zum Zitat Kolho KL, Raivio T, Lindahl H, Savilahti E. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol. 2006;41:720–725.PubMedCrossRef Kolho KL, Raivio T, Lindahl H, Savilahti E. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol. 2006;41:720–725.PubMedCrossRef
26.
Zurück zum Zitat Ashorn S, Honkanen T, Kolho KL, et al. Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:199–205.PubMedCrossRef Ashorn S, Honkanen T, Kolho KL, et al. Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:199–205.PubMedCrossRef
27.
Zurück zum Zitat Diamanti A, Panetta F, Basso MS, et al. Diagnostic work-up of inflammatory bowel disease in children: the role of calprotectin assay. Inflamm Bowel Dis. 2010;16:1926–1930.PubMedCrossRef Diamanti A, Panetta F, Basso MS, et al. Diagnostic work-up of inflammatory bowel disease in children: the role of calprotectin assay. Inflamm Bowel Dis. 2010;16:1926–1930.PubMedCrossRef
28.
Zurück zum Zitat Grogan JL, Casson DH, Terry A, Burdge GC, El-Matary W, Dalzell AM. Enteral feeding therapy for newly diagnosed pediatric Crohn’s disease: a double-blind randomized controlled trial with two years follow-up. Inflamm Bowel Dis. 2012;18:246–253.PubMedCrossRef Grogan JL, Casson DH, Terry A, Burdge GC, El-Matary W, Dalzell AM. Enteral feeding therapy for newly diagnosed pediatric Crohn’s disease: a double-blind randomized controlled trial with two years follow-up. Inflamm Bowel Dis. 2012;18:246–253.PubMedCrossRef
29.
Zurück zum Zitat Canani RB, Rapacciuolo L, Romano MT, et al. Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice. Dig Liver Dis. 2004;36:467–470.CrossRef Canani RB, Rapacciuolo L, Romano MT, et al. Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice. Dig Liver Dis. 2004;36:467–470.CrossRef
30.
Zurück zum Zitat Perminow G, Brackmann S, Lyckander LG, et al. A characterization in childhood inflammatory bowel disease, a new population-based inception cohort from South-Eastern Norway, 2005–07, showing increased incidence in Crohn’s disease. Scand J Gastroenterol. 2009;44:446–456.PubMedCrossRef Perminow G, Brackmann S, Lyckander LG, et al. A characterization in childhood inflammatory bowel disease, a new population-based inception cohort from South-Eastern Norway, 2005–07, showing increased incidence in Crohn’s disease. Scand J Gastroenterol. 2009;44:446–456.PubMedCrossRef
31.
Zurück zum Zitat Carroccio A, Iacono G, Cottone M, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem. 2003;49:861–867.PubMedCrossRef Carroccio A, Iacono G, Cottone M, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem. 2003;49:861–867.PubMedCrossRef
32.
Zurück zum Zitat Paduchova Z, Durackova Z. Fecal calprotectin as a promising marker of inflammatory diseases. Bratisl Lek Listy. 2009;110:598–602.PubMed Paduchova Z, Durackova Z. Fecal calprotectin as a promising marker of inflammatory diseases. Bratisl Lek Listy. 2009;110:598–602.PubMed
33.
Zurück zum Zitat Sipponen T, Kolho KL. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol. 2010;45:872–877.PubMedCrossRef Sipponen T, Kolho KL. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol. 2010;45:872–877.PubMedCrossRef
34.
Zurück zum Zitat Vitali R, Stronati L, Negroni A, et al. Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease. Am J Gastroenterol. 2011;106:2029–2040.PubMedCrossRef Vitali R, Stronati L, Negroni A, et al. Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease. Am J Gastroenterol. 2011;106:2029–2040.PubMedCrossRef
35.
Zurück zum Zitat Diamanti A, Colistro F, Basso MS, et al. Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases. Inflamm Bowel Dis. 2008;14:1229–1235.PubMedCrossRef Diamanti A, Colistro F, Basso MS, et al. Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases. Inflamm Bowel Dis. 2008;14:1229–1235.PubMedCrossRef
36.
Zurück zum Zitat Nissen AC, van Gils CE, Menheere PP, van den Neucker AM, van der Hoeven MA, Forget PP. Fecal calprotectin in healthy term and preterm infants. J Pediatr Gastroenterol Nutr. 2004;38:107–108.PubMedCrossRef Nissen AC, van Gils CE, Menheere PP, van den Neucker AM, van der Hoeven MA, Forget PP. Fecal calprotectin in healthy term and preterm infants. J Pediatr Gastroenterol Nutr. 2004;38:107–108.PubMedCrossRef
37.
Zurück zum Zitat Diamanti A, Knafelz D, Panetta F, et al. Plasma citrulline as surrogate marker of intestinal inflammation in pediatric and adolescent with Crohn’s disease: preliminary report. Int J Colorectal Dis. 2011;26:1445–1451.PubMedCrossRef Diamanti A, Knafelz D, Panetta F, et al. Plasma citrulline as surrogate marker of intestinal inflammation in pediatric and adolescent with Crohn’s disease: preliminary report. Int J Colorectal Dis. 2011;26:1445–1451.PubMedCrossRef
38.
Zurück zum Zitat Tomomasa T, Tajiri H, Kagimoto S, et al. Leukocytapheresis in pediatric patients with ulcerative colitis. J Pediatr Gastroenterol Nutr. 2011;53:34–39.PubMedCrossRef Tomomasa T, Tajiri H, Kagimoto S, et al. Leukocytapheresis in pediatric patients with ulcerative colitis. J Pediatr Gastroenterol Nutr. 2011;53:34–39.PubMedCrossRef
39.
Zurück zum Zitat Bremner A, Roked S, Robinson R, Phillips I, Beattie M. Faecal calprotectin in children with chronic gastrointestinal symptoms. Acta Paediatr. 2005;94:1855–1858.PubMedCrossRef Bremner A, Roked S, Robinson R, Phillips I, Beattie M. Faecal calprotectin in children with chronic gastrointestinal symptoms. Acta Paediatr. 2005;94:1855–1858.PubMedCrossRef
40.
Zurück zum Zitat Joishy M, Davies I, Ahmed M, et al. Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;48:48–54.PubMedCrossRef Joishy M, Davies I, Ahmed M, et al. Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;48:48–54.PubMedCrossRef
41.
Zurück zum Zitat Gerasimidis K, Nikolaou CK, Edwards CA, McGrogan P. Serial fecal calprotectin changes in children with Crohn’s disease on treatment with exclusive enteral nutrition: associations with disease activity, treatment response, and prediction of a clinical relapse. J Clin Gastroenterol. 2011;45:234–239.PubMedCrossRef Gerasimidis K, Nikolaou CK, Edwards CA, McGrogan P. Serial fecal calprotectin changes in children with Crohn’s disease on treatment with exclusive enteral nutrition: associations with disease activity, treatment response, and prediction of a clinical relapse. J Clin Gastroenterol. 2011;45:234–239.PubMedCrossRef
42.
Zurück zum Zitat Fagerberg UL, Lööf L, Lindholm J, Hansson LO, Finkel Y. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;45:414–420.PubMedCrossRef Fagerberg UL, Lööf L, Lindholm J, Hansson LO, Finkel Y. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;45:414–420.PubMedCrossRef
43.
Zurück zum Zitat Olafsdottir E, Aksnes L, Fluge G, Berstad A. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatr. 2002;91:45–50.PubMedCrossRef Olafsdottir E, Aksnes L, Fluge G, Berstad A. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatr. 2002;91:45–50.PubMedCrossRef
44.
Zurück zum Zitat Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut. 2010;59:1207–1212.PubMedCrossRef Turner D, Leach ST, Mack D, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut. 2010;59:1207–1212.PubMedCrossRef
45.
Zurück zum Zitat Bunn SK, Bisset WM, Main MJ, Gray ES, Olson S, Golden BE. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;33:14–22.PubMedCrossRef Bunn SK, Bisset WM, Main MJ, Gray ES, Olson S, Golden BE. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;33:14–22.PubMedCrossRef
46.
Zurück zum Zitat Bunn SK, Bisset WM, Main MJ, Golden BE. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;32:171–177.PubMedCrossRef Bunn SK, Bisset WM, Main MJ, Golden BE. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;32:171–177.PubMedCrossRef
47.
Zurück zum Zitat Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010;138:2282–2291.PubMedCrossRef Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010;138:2282–2291.PubMedCrossRef
48.
Zurück zum Zitat Canani RB, Terrin G, Rapacciuolo L, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008;40:547–553.PubMedCrossRef Canani RB, Terrin G, Rapacciuolo L, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008;40:547–553.PubMedCrossRef
49.
Zurück zum Zitat Wiskin AE, Wootton SA, Cornelius VR, Afzal NA, Elia M, Beattie RM. No relation between disease activity measured by multiple methods and REE in childhood Crohn disease. J Pediatr Gastroenterol Nutr. 2012;54:271–276.PubMedCrossRef Wiskin AE, Wootton SA, Cornelius VR, Afzal NA, Elia M, Beattie RM. No relation between disease activity measured by multiple methods and REE in childhood Crohn disease. J Pediatr Gastroenterol Nutr. 2012;54:271–276.PubMedCrossRef
50.
Zurück zum Zitat Walkiewicz D, Werlin SL, Fish D, Scanlon M, Hanaway P, Kugathasan S. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:669–673.PubMedCrossRef Walkiewicz D, Werlin SL, Fish D, Scanlon M, Hanaway P, Kugathasan S. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:669–673.PubMedCrossRef
51.
Zurück zum Zitat Aomatsu T, Yoden A, Matsumoto K, et al. Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig Dis Sci. 2011;56:2372–2377.PubMedCrossRef Aomatsu T, Yoden A, Matsumoto K, et al. Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig Dis Sci. 2011;56:2372–2377.PubMedCrossRef
52.
Zurück zum Zitat Kostakis ID, Cholidou KG, Kallianidis K, Perrea D, Antsaklis A. The role of calprotectin in obstetrics and gynecology. Eur J Obstet Gynecol Reprod Biol. 2010;151:3–9.PubMedCrossRef Kostakis ID, Cholidou KG, Kallianidis K, Perrea D, Antsaklis A. The role of calprotectin in obstetrics and gynecology. Eur J Obstet Gynecol Reprod Biol. 2010;151:3–9.PubMedCrossRef
53.
Zurück zum Zitat McCormick MM, Rahimi F, Bobryshev YV, et al. S100A8 and S100A9 in human arterial wall. Implications for atherogenesis. J Biol Chem. 2005;280:41521–41529.PubMedCrossRef McCormick MM, Rahimi F, Bobryshev YV, et al. S100A8 and S100A9 in human arterial wall. Implications for atherogenesis. J Biol Chem. 2005;280:41521–41529.PubMedCrossRef
54.
Zurück zum Zitat Ehrchen JM, Sunderkötter C, Foell D, Vogl T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009;86:557–566.PubMedCrossRef Ehrchen JM, Sunderkötter C, Foell D, Vogl T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009;86:557–566.PubMedCrossRef
55.
Zurück zum Zitat Stríz I, Trebichavský I. Calprotectin - a pleiotropic molecule in acute and chronic inflammation. Physiol Res. 2004;53:245–253.PubMed Stríz I, Trebichavský I. Calprotectin - a pleiotropic molecule in acute and chronic inflammation. Physiol Res. 2004;53:245–253.PubMed
56.
Zurück zum Zitat Kannan S. Inflammation: a novel mechanism for the transport of extracellular nucleotide-induced arachidonic acid by S100A8/A9 for transcellular metabolism. Cell Biol Int. 2003;27:593–595.PubMedCrossRef Kannan S. Inflammation: a novel mechanism for the transport of extracellular nucleotide-induced arachidonic acid by S100A8/A9 for transcellular metabolism. Cell Biol Int. 2003;27:593–595.PubMedCrossRef
57.
Zurück zum Zitat Katashima T, Naruko T, Terasaki F, et al. Enhanced expression of the S100A8/A9 complex in acute myocardial infarction patients. Circ J. 2010;74:741–748.PubMedCrossRef Katashima T, Naruko T, Terasaki F, et al. Enhanced expression of the S100A8/A9 complex in acute myocardial infarction patients. Circ J. 2010;74:741–748.PubMedCrossRef
58.
Zurück zum Zitat Croce K, Gao H, Wang Y, et al. Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation. 2009;120:427–436.PubMedCrossRef Croce K, Gao H, Wang Y, et al. Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation. 2009;120:427–436.PubMedCrossRef
59.
Zurück zum Zitat Baumann M, Schmaderer C, Burkhardt K, et al. MRP8/14 is associated with systemic inflammation in stable coronary atherosclerosis in men. Eur J Clin Invest. 2011;41:1261–1267.PubMedCrossRef Baumann M, Schmaderer C, Burkhardt K, et al. MRP8/14 is associated with systemic inflammation in stable coronary atherosclerosis in men. Eur J Clin Invest. 2011;41:1261–1267.PubMedCrossRef
60.
Zurück zum Zitat Ehlermann P, Eggers K, Bierhaus A, et al. Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc Diabetol. 2006;5:6.PubMedCrossRef Ehlermann P, Eggers K, Bierhaus A, et al. Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc Diabetol. 2006;5:6.PubMedCrossRef
61.
Zurück zum Zitat van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010;341:c3369.PubMedCrossRef van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010;341:c3369.PubMedCrossRef
Metadaten
Titel
Fecal Calprotectin in Pediatric Inflammatory Bowel Disease: A Systematic Review
verfasst von
Ioannis D. Kostakis
Kyriaki G. Cholidou
Aristeidis G. Vaiopoulos
Ioannis S. Vlachos
Despina Perrea
George Vaos
Publikationsdatum
01.02.2013
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 2/2013
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2347-5

Weitere Artikel der Ausgabe 2/2013

Digestive Diseases and Sciences 2/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.